Welcome to our dedicated page for Vicarious Surgical news (Ticker: RBOT), a resource for investors and traders seeking the latest updates and insights on Vicarious Surgical stock.
Vicarious Surgical Inc (RBOT) combines advanced robotics with virtual reality to transform minimally invasive surgery. This news hub provides investors and healthcare professionals with essential updates about the company's technological advancements and market position.
Access real-time information about surgical robotics innovations, regulatory milestones, and strategic partnerships. Our curated collection includes earnings reports, product development announcements, and clinical trial updates directly impacting the future of abdominal surgery techniques.
Key focus areas include 3D visualization systems, single-port surgical interfaces, and integration with existing hospital workflows. Stay informed about developments in robotic-assisted procedures that enhance surgical precision while reducing patient recovery times.
Bookmark this page for verified updates about RBOT's progress in medical robotics. Regularly updated content ensures you maintain current awareness of technological breakthroughs and industry partnerships shaping modern surgical practices.
Vicarious Surgical (NYSE: RBOT) updated full-year 2025 financial guidance, now expecting cash burn of approximately $45 million, an improvement of $5 million from prior guidance of $50 million driven by disciplined cost management and an operational reset.
The company said it will provide full-year 2026 cash burn guidance before year-end to give investors visibility into the next phase. The Board also made committee appointments: Victoria Carr-Brendel as Compensation Committee chair, Fuad Ahmad to the Compensation Committee, and Joseph Doherty to the Audit Committee.
Vicarious Surgical (NYSE: WS) will participate in the Piper Sandler 37th Annual Healthcare Conference. Management is scheduled for a fireside discussion on Wednesday, December 3, 2025 at 4:30 PM ET. Interested parties can listen to a live audio webcast via the company’s investor site under Events & Presentations at the provided investor URL.
This announcement confirms the company’s investor outreach and provides the date, time, and webcast access for attendees and investors.
Vicarious Surgical (NYSE: RBOT, RBOT WS) reported third quarter 2025 results on November 12, 2025. The company reported total operating expenses of $11.5 million in Q3 2025, down 35% year-over-year, and a GAAP net loss of $11.1 million ($1.86 per share), improved from $17.1 million a year earlier. Management said it has begun implementation of a plan to reduce burn and reached design freeze progress.
The company raised $5.9 million in gross proceeds from a registered direct offering in October, held $13.4 million of cash and investments as of September 30, 2025, and recorded a Q3 cash burn of $10.5 million. Vicarious Surgical expects full-year 2025 cash burn of approximately $50 million. Management hosted a conference call on November 12, 2025.
Vicarious Surgical (NYSE: WS) will report financial results for the third quarter ended September 30, 2025 after market close on Wednesday, November 12, 2025.
Management will host a conference call beginning at 4:30 p.m. Eastern Time. Domestic callers may dial +1 833-470-1428, international callers +1 404-975-4839, using access code 623856. A live and archived webcast will be available at https://investor.vicarioussurgical.com.
Vicarious Surgical (NYSE: RBOT, RBOT WS) announced it will report third quarter 2025 financial results for the period ended September 30, 2025 after market close on Thursday, November 13, 2025. Management will host a conference call beginning at 4:30 p.m. Eastern Time the same day.
Investors can join by dialing +1 833-470-1428 (domestic) or +1 404-975-4839 (international) with access code 623856. A live and archived webcast will be available at https://investor.vicarioussurgical.com.
Vicarious Surgical (NYSE: RBOT) announced a registered direct offering and concurrent private placement expected to raise approximately $5.9 million gross proceeds. The company agreed to sell 1,150,000 shares of Class A common stock (or pre-funded warrants) at a combined effective price of $5.10 per share with accompanying warrants. Pre-funded warrants are priced at $5.0999. The private placement will issue Series A and Series B common warrants to purchase up to 1,150,000 shares each (total up to 2,300,000 shares) at a $5.10 exercise price, exercisable upon stockholder approval and expiring five years after approval. Series B warrants include a repurchase provision at $0.01 per underlying share upon specified stock-price/volume milestones. Lake Street Capital Markets is the placement agent. Closing expected on or about October 9, 2025, subject to customary conditions and NYSE authorization. Proceeds intended for general corporate purposes.
Vicarious Surgical (NYSE:RBOT) has appointed Joseph Doherty as Chairman of the Board of Directors. Doherty, who joined the board in June 2025, brings extensive healthcare and medical device industry experience, having served as CEO of Worcester City Campus Corporation and President of Scapa Healthcare.
His background includes leadership roles at Olympus Surgical Technologies America and a 24-year tenure at Johnson & Johnson, where he served as Vice President of Integration and Transformation. Doherty holds a BS in Engineering from West Point and an MBA from Nichols College.
Vicarious Surgical (NYSE:RBOT), a next-generation robotics technology company focused on transforming robotic surgery, has announced its participation in the upcoming H.C. Wainwright 27th Annual Global Investment Conference in New York.
The company's management team will deliver a presentation on Wednesday, September 10, 2025 at 9:00 a.m. ET. Investors and interested parties can access the live audio webcast through the Events & Presentations section of Vicarious Surgical's investor relations website.
Vicarious Surgical (NYSE: RBOT) reported its Q2 2025 financial results, marking a significant transition in leadership as Adam Sachs moves to President and Stephen From takes over as CEO. The surgical robotics company reported a GAAP net loss of $13.2 million ($2.23 per share), improving from a $15.2 million loss in Q2 2024.
Operating expenses decreased 24% to $13.5 million, with R&D expenses at $9.1 million, G&A at $4.1 million, and sales/marketing at $0.3 million. The company ended Q2 with $24.0 million in cash and investments, reporting a quarterly cash burn of $13.4 million. Management projects full-year 2025 cash burn of approximately $50 million.
[ "Net loss improved from $15.2M in Q2 2024 to $13.2M in Q2 2025", "Operating expenses reduced by 24% year-over-year", "Sales and marketing expenses decreased significantly from $1.2M to $0.3M" ]Vicarious Surgical (NYSE: RBOT) has appointed Stephen From as its new Chief Executive Officer and Board member, effective August 7, 2025. Current CEO and Co-Founder Adam Sachs will transition to the role of President while remaining on the Board. From brings over 20 years of healthcare and financial industry leadership experience, most recently serving as CEO of Aruna Bio.
From's extensive background includes serving as President, CEO, and Executive Chairman of Kiora Pharmaceuticals, where he led the company through its IPO and multiple acquisitions. He previously held positions as CFO of Centelion SAS and worked in investment banking at Bank of America Securities and Robertson Stephens.
As part of his appointment, From will receive a stock option award for 297,600 shares of Class A common stock, vesting over four years, as a material inducement to his employment.
FAQ
What is the current stock price of Vicarious Surgical (RBOT)?
What is the market cap of Vicarious Surgical (RBOT)?
